Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

30 Sep 2020 14:27

RNS Number : 6378A
Motif Bio PLC
30 September 2020
 

 

 

Motif Bio plc

 

("Motif Bio" or the "Company")

 

Result of AGM

 

Motif Bio plc (AIM: MTFB) announces that at the Annual General Meeting of the Company held earlier today at the offices of ONE Advisory Limited, 201 Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT all but one of the resolutions put to members were passed on a poll.

 

The Board notes that resolution 7, which was proposed as a special resolution regarding the disapplication of pre-emption rights, was not passed.

 

The number of votes lodged by proxy and voted on by poll for and against each of the resolutions proposed, and the number of votes withheld, were as follows:

 

Resolution

FOR*

%

AGAINST

%

WITHHELD

Resolution 1 (Ordinary)

To receive the Company's annual accounts and the strategic, directors' and auditors' reports for the year ended 31 December 2019.

 

37,371,686

 

91.94

 

 

3,275,355

 

8.06

 

 

131,590

Resolution 2 (Ordinary)

To re-elect Graham Lumsden as a Director of the Company

 

27, 167,596

 

66.74

 

 

13,541,866

 

33.26

 

 

69,169

Resolution 3 (Ordinary)

To re-elect Christopher Wardhaugh as a director of the Company, who was appointed by the board since the last annual general meeting.

 

 

34,740,854

 

 

85.42

 

 

 

5,930,684

 

 

14.58

 

 

 

107,093

Resolution 4 (Ordinary)

To re-appoint the Company's auditor Crowe LLP, who have been appointed by the board since the last annual general meeting.

 

 

37,286,396

 

 

91.56

 

 

 

 

3,437,066

 

 

8.44

 

 

 

55,169

Resolution 5 (Ordinary)

That the Directors be authorised to fix the auditors remuneration.

 

36,844,682

 

 

90.71

 

 

 

3,772,431

 

9.29

 

 

161,518

Resolution 6 (Ordinary)

To empower the directors to allot relevant securities pursuant to Section 551 of the Act

 

33,534,192

 

84.95

 

 

5,941,430

 

 

15.05

 

 

1,303,009

Resolution 7 (Special)

To disapply the pre-emptive rights contained in Section 561 of the Act

 

26,246,162

 

73.09

 

 

 

9,844,855

 

26.91

 

 

4,187,614

 

 

 

*including votes granting discretion to the chair

 

As at 30 September 2020, there were 654,991,023 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

 

 This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information please contact:

 

Motif Bio plc

 

ir@motifbio.com

Jonathan Gold (President and Chief Business Officer)

 

 

 

 

SP Angel Corporate Finance LLP (NOMAD & BROKER)

 

+44 (0) 20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Abigail Wayne (Sales & Broking)

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0) 20 7933 8780

Paul McManus/ Lianne Cawthorne

motifbio@walbrookpr.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBXGDCXDXDGGG
Date   Source Headline
30th Sep 20194:35 pmRNSPrice Monitoring Extension
30th Sep 20192:22 pmRNSHalf-year Report
17th Sep 20194:41 pmRNSSecond Price Monitoring Extn
17th Sep 20194:35 pmRNSPrice Monitoring Extension
4th Sep 20192:57 pmRNSHolding(s) in Company
2nd Sep 20197:00 amRNSAmended Loan and Security Agreement
30th Aug 20194:41 pmRNSSecond Price Monitoring Extn
30th Aug 20194:35 pmRNSPrice Monitoring Extension
19th Aug 20197:00 amRNSNIH to Evaluate Iclaprim Activity against Listeria
1st Aug 20197:00 amRNSAmended Loan and Security Agreement
26th Jul 20197:00 amRNSMotif Bio Confirms Meeting Date with U.S. FDA
26th Jul 20197:00 amRNSReceipt of Deficiency Notice from Nasdaq
19th Jul 20197:00 amRNSMotif Bio-Receipt of Deficiency Notice from Nasdaq
18th Jul 20194:30 pmRNSHolding(s) in Company
15th Jul 20197:00 amRNSUS FDA meeting request and package submitted
28th Jun 20195:13 pmRNSHolding(s) in Company
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:36 pmRNSPrice Monitoring Extension
26th Jun 201912:07 pmRNSSecond Price Monitoring Extn
26th Jun 201912:02 pmRNSPrice Monitoring Extension
24th Jun 20197:00 amRNSMotif Bio Presents New Iclaprim Data - ASM Microbe
20th Jun 20194:35 pmRNSPrice Monitoring Extension
19th Jun 20195:08 pmRNSHolding(s) in Company
18th Jun 20194:05 pmRNSHolding(s) in Company
14th Jun 20199:04 amRNSHolding(s) in Company
12th Jun 20195:52 pmRNSHolding(s) in Company
6th Jun 20197:00 amRNSReceipt of FDA Meeting Minutes
31st May 20193:15 pmRNSResult of AGM
31st May 201910:28 amRNSHolding(s) in Company
29th May 201911:36 amRNSHolding(s) in Company
22nd May 20191:50 pmRNSAGM Statement
22nd May 20197:00 amRNSOrphan Disease Opportunity for Iclaprim
21st May 20197:00 amRNSIclaprim Data presented at ASM Microbe 2019
20th May 20196:14 pmRNSHolding(s) in Company
3rd May 20196:25 pmRNSMeeting with US FDA held as planned
1st May 20197:00 amRNSMotif Signs Agreement with Lamellar Biomedical
26th Apr 20197:01 amRNSNotice of AGM
26th Apr 20197:00 amRNSAppointment of Andrew Powell to Board of Directors
16th Apr 20197:00 amRNSMotif Presents New Iclaprim Data at ECCMID 2019
15th Apr 20197:00 amRNSFiscal Year 2018 Results
4th Apr 20197:00 amRNSMotif Bio to Present Iclaprim Data at ECCMID 2019
2nd Apr 20195:43 pmRNSHolding(s) in Company
1st Apr 20193:28 pmRNSHolding(s) in Company
1st Apr 20192:17 pmRNSHolding(s) in Company
26th Mar 20197:00 amRNSMotif Bio Raises £2.7m (US$3.55m)
25th Mar 20199:49 amRNSProposed Equity Fundraise
20th Mar 20197:00 amRNSHolding(s) in Company
20th Mar 20197:00 amRNSMotif Bio Granted Meeting with U.S. FDA
18th Mar 20197:00 amRNSAppointment of Bruce Williams as Interim Chairman
15th Mar 20197:01 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.